Search results for AAA2026
AAA2026 community
One keyword maps to one global community path.
People
Not Found
Tweets including AAA2026
With #ADA2026# right around the corner, now’s the perfect time to familiarize yourself with the latest in ketone monitoring with our free, CME-accredited masterclass series; designed to enhance your confidence and decision-making:
Show more
[🎬] [#AAA2025#] ATEEZ(에이티즈) - ‘Man on Fire+Dance Break+ In Your Fantasy’ Broadcast Stage | Official Video
#ATEEZ# #에이티즈#
#2025AsiaArtistAwards#
The conversations at #ADA2026# are helping to build a new era of care.
[📺YENA VOD]
[#aaa2025#] YENA(최예나) - 4K Award acceptance speech
🔗
#최예나# #예나# #YENA#
#2025AsiaArtistAwards#
#AAA2025_KAOHSIUNG# #AAA_10th#
That’s a wrap on #ADA2026#. It left us with important reminders about why science matters and who it’s for. #WeAreLilly#
NEW Phase 3 data today at #ADA2026#: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more:
Show more
New data: Our oral GLP-1 delivered superior A1C control and weight loss across three clinical trials. Read more: #ADA2026#
Women at every stage of menopause — pre, peri and post — experienced meaningful weight loss in post-hoc analyses of two studies of one of our obesity medicines presented at #ADA2026#. Up to 30 pounds lost on the highest dose at 72 weeks. Read more:
Show more
Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026# and published simultaneously in @TheLancet. Read more:
Show more
In addition to weight loss, our investigational triple agonist reduced moderate-to-severe obstructive sleep apnea severity by an average 61 percent on the 9 mg dose in the TRIUMPH-1 study. Presented today at #ADA2026#. Read more:
Show more
